Sunitinib shows efficacy in the treatment of Advanced Neuroendocrine Tumors

Sunitinib has shown efficacy in a phase II study of pancreatic neuroendocrine tumor patients.

Merck-Serono initiate Phase III trial of Erbitux in Gastric Cancer

Merck KGaA (Merck-Serono) has initiated a Phase III study of Erbitux in combination with Xeloda and Cisplatin for the treatment of gastric tumors.